Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, October 18 '25)

Image
By G.M.

 


    AJR Am J Roentgenol

  1. LITTLE BP
    Imaging and Reporting of Post-COVID-19 Lung Abnormalities at CT: International Panel of Experts Provides Welcome Guidance.
    AJR Am J Roentgenol. 2025 Oct 15. doi: 10.2214/AJR.25.33999.
    PubMed        


    Infect Control Hosp Epidemiol

  2. ELHAISSOUNI N, Arthur A, Prochaska EC, Colantuoni E, et al
    Association of pandemic precautions and Staphylococcus aureus in the NICU.
    Infect Control Hosp Epidemiol. 2025 Oct 13:1-3. doi: 10.1017/ice.2025.10319.
    PubMed         Abstract available


    Int J Infect Dis

  3. OPPONG AE, Coelewij L, Hutchinson M, Carpenter B, et al
    Simple hyperinflammation scores predict mortality in hospitalised patients with COVID-19 and offer a personalised medicine approach to dexamethasone intervention.
    Int J Infect Dis. 2025 Oct 13:108119. doi: 10.1016/j.ijid.2025.108119.
    PubMed         Abstract available


    J Infect

  4. TANG X, Ma T, Yao Z, Zhang L, et al
    The triumvirate of mutation bias, population dynamics, and natural selection in shaping SARS-CoV-2 intra-host variation.
    J Infect. 2025;91:106628.
    PubMed        


    J Med Virol

  5. GAKLIK LTA, Carneiro BM
    Assessing Influenza and SARS-CoV-2 Coinfection in Brazil: A Comprehensive Study of Patient Outcomes From 2020 to 2023.
    J Med Virol. 2025;97:e70639.
    PubMed         Abstract available

  6. PARRY RH, Shang Y, Sng JDJ, McMillan CLD, et al
    Vaccine-Induced and Hybrid Immunity Against SARS-CoV-2 Variants of Concern in Two Cohorts in Queensland, Australia (2021-2022).
    J Med Virol. 2025;97:e70642.
    PubMed         Abstract available

  7. CHEN W, Li J, Bai S, Zhang A, et al
    Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine.
    J Med Virol. 2025;97:e70638.
    PubMed         Abstract available


    J Virol

  8. DING S, Yang D, Ullah I, Niu L, et al
    Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.
    J Virol. 2025 Oct 13:e0103425. doi: 10.1128/jvi.01034.
    PubMed         Abstract available

  9. DADONAITE B, Harari S, Larsen BB, Kampman L, et al
    Spike mutations that affect the function and antigenicity of recent KP.3.1.1-like SARS-CoV-2 variants.
    J Virol. 2025 Oct 13:e0142325. doi: 10.1128/jvi.01423.
    PubMed         Abstract available

  10. YU J, Sun Q, Zhu J, Cui Y, et al
    The integrin protein ITGbeta1 effectively suppresses porcine epidemic diarrhea virus replication through facilitating MDA5 oligomerization and subsequent activation of the type I interferon signaling pathway.
    J Virol. 2025 Oct 17:e0155325. doi: 10.1128/jvi.01553.
    PubMed         Abstract available


    JAMA

  11. SAUGEL B, Meidert AS, Brunkhorst FM, Bischoff R, et al
    Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial.
    JAMA. 2025 Oct 12:e2517235. doi: 10.1001/jama.2025.17235.
    PubMed         Abstract available


    Lancet

  12. THE LANCET
    Health progress in a post-COVID-19 world.
    Lancet. 2025 Oct 12:S0140-6736(25)01947-6. doi: 10.1016/S0140-6736(25)01947.
    PubMed        


  13. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    PubMed         Abstract available


  14. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    PubMed         Abstract available


  15. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    PubMed         Abstract available

  16. REHM J, Assanangkornchai S, Hendershot CS, Franklin A, et al
    Alcohol use disorders.
    Lancet. 2025 Oct 9:S0140-6736(25)01496-5. doi: 10.1016/S0140-6736(25)01496.
    PubMed         Abstract available

  17. RANDERATH W, Grote L, Stenlof K, Fietze I, et al
    Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial.
    Lancet. 2025 Oct 9:S0140-6736(25)01196-1. doi: 10.1016/S0140-6736(25)01196.
    PubMed         Abstract available

  18. NDEMBI N, Mercy K, Folayan MO, Abdool Karim SS, et al
    Analysis of mpox in Angola conflates distinct timelines.
    Lancet. 2025;406:e29.
    PubMed        


    Lancet Infect Dis

  19. SCHILLING WHK, Jittamala P, Wongnak P, Watson JA, et al
    Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00482.
    PubMed         Abstract available

  20. HONG CM, Hung IFN
    Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00549.
    PubMed        
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »